ABCA4 DNA nanoparticles (Copernicus Therapeutics)

N/A

Report date: 2025/01/15 20:00:32
NME

Base Information

Drug NameABCA4 DNA nanoparticles (Copernicus Therapeutics)
Drug Alias NameABCA4 DNA nanoparticles (Stargardt disease), Copernicus Therapeutics
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionRetinal-specific phospholipid-transporting ATPase ABCA4 stimulants
TargetsRetinal-specific phospholipid-transporting ATPase ABCA4
Therapy Area/IndicationsStargardt Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCopernicus Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCopernicus Therapeutics
Active IndicationsN/A
Inactive IndicationsStargardt Disease

Other Information

ATC CodeN/A
Related LinksN/A